Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

2VIV

Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator

2VIV の概要
エントリーDOI10.2210/pdb2viv/pdb
関連するPDBエントリー1C5W 1C5X 1C5Y 1C5Z 1EJN 1F5L 1F92 1FV9 1GI7 1GI8 1GI9 1GJ7 1GJ8 1GJ9 1GJA 1GJB 1GJC 1GJD 1KDU 1LMW 1O3P 1O5A 1O5B 1O5C 1OWD 1OWE 1OWH 1OWI 1OWJ 1OWK 1SC8 1SQA 1SQO 1SQT 1U6Q 1VJ9 1VJA 1W0Z 1W10 1W11 1W12 1W13 1W14 2JDE 2VIN 2VIO 2VIP 2VIQ 2VIW
分子名称UROKINASE-TYPE PLASMINOGEN ACTIVATOR CHAIN B, ACETATE ION, 4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide, ... (4 entities in total)
機能のキーワードplasminogen activation, egf-like domain, blood coagulation, inhibitor, polymorphism, glycoprotein, fibrinolysis, kringle, zymogen, secreted, protease, hydrolase, urokinase-type plasminogen activator, pharmaceutical, serine protease, phosphorylation
由来する生物種HOMO SAPIENS (HUMAN)
細胞内の位置Secreted: P00749
タンパク質・核酸の鎖数1
化学式量合計28905.32
構造登録者
Frederickson, M.,Callaghan, O.,Chessari, G.,Congreve, M.,Cowan, S.R.,Matthews, J.E.,McMenamin, R.,Smith, D.,Vinkovic, M.,Wallis, N.G. (登録日: 2007-12-05, 公開日: 2008-01-22, 最終更新日: 2024-11-06)
主引用文献Frederickson, M.,Callaghan, O.,Chessari, G.,Congreve, M.,Cowan, S.R.,Matthews, J.E.,Mcmenamin, R.,Smith, D.,Vinkovic, M.,Wallis, N.G.
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-Type Plasminogen Activator.
J.Med.Chem., 51:183-, 2008
Cited by
PubMed Abstract: Fragment-based lead discovery has been applied to urokinase-type plasminogen activator (uPA). The (R)-enantiomer of the orally active drug mexiletine 5 (a fragment hit from X-ray crystallographic screening) was the chemical starting point. Structure-aided design led to elaborated inhibitors that retained the key interactions of (R)-5 while gaining extra potency by simultaneously occupying neighboring regions of the active site. Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA.
PubMed: 18163548
DOI: 10.1021/JM701359Z
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.72 Å)
構造検証レポート
Validation report summary of 2viv
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon